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Abstract
During faecal microbiota transplantation, stool from a healthy donor is transplanted to treat a variety of dysbiosis-
associated gut diseases. Competent authorities are faced with the challenge to provide adequate regulation.
Currently, regulatory harmonization is completely lacking and authorities apply non-existing to most stringent
requirements. A regulatory approach for faecal microbiota transplantation could be inserting faecal microbiota
transplantation in the gene-, cell- and tissue regulations, including the hospital exemption system in the European
Advanced Therapy Medicinal Products regulation, providing a pragmatic and efficacy-risk balanced approach and
granting all patients as a matter of principle access to this therapy.
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Faecal microbiota transplantation
The microbiome is no longer considered a passive co-
existing community and the idea that these bacteria are
idle bystanders clearly belongs to the past. A hallmark is
the initiation of the Human Microbiome Project in
2007, aiming to unravel the microbial communities in
and on the human body [1]. Exploration of the human
microbiome and the relation with the host drastically
changed the view towards these microbial cohabitants.
Discoveries concerning the role of the microbiome in
health and disease provide possibilities towards treatment
of several diseases where a profound role is believed to be
played by the human microbiome, or a misbalance of the
microbiome is at the basis of the condition. In particular,
various diseases are linked to an alteration of the gut
microbiome, e.g. irritable bowel syndrome, intestinal
infections and inflammatory bowel disease [2–7].
Antibiotic-associated nosocomial diarrhoea and colitis
are frequently caused by a Clostridium difficile infec-
tion, a result of gut microbiota dysbiosis [8–10]. The
medical signs can range from an asymptomatic carrier
state to pseudomembranous colitis and toxic megacolon
[11]. Characterised with a mortality up to 40%, influenced
by strain and host clinical status, C. difficile infection was
estimated to be accountable for approximately 500,000
infections and nearly 30,000 deaths in the USA in 2011
[12]. C. difficile infection is associated with significant fi-
nancial consequences as well in the USA [13–17]. Based
on the meta-analysis and cost-modelling study by Zhang
et al. (2016), the inpatient management alone accounts for
an estimated US$ 6.3 billion, a total of 2.4 million days of
hospitalization, and the total disease management comes
with a cost of US$ 12.4 billion in 2015 in the USA [13].
The occurrence of C. difficile infections in Canada are
considered to be similar to the infection rates in the USA,
with an estimated annual infection rate of approximately
37,900 cases in 2012 and accounting for a financial burden
of CAD$ 280 million [18]. In the European Union,
200,000 individuals are estimated to be infected annu-
ally, based on the incidence of C. difficile in the United
Kingdom in 2011–2012 [19]. The most recent cost esti-
mation of C. difficile infection in the entire European
Union already dates back to 2006, Kuijper et al. estimated
the total financial burden caused by C. difficile infection to
be € 3 billion [20]. From 2006 onwards, several cost es-
timates have been published, focussing on individual in-
stitutions and European individual nations or a limited
number of European countries [21–25]. C. difficile infec-
tions have long been perceived to be a matter of Europe
and North-America, whereas the infection rate in Asia
remained largely unknown. However, Borren et al.
showed, with their systematic review and meta-analysis
in 2017, that Asia is affected by a similar infection rate
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[26]. However, estimates on the financial burden of C.
difficile infection in Asia are to our knowledge not re-
ported. Additionally, the burden and financial costs liable
to C. difficile infection in South-America and Africa have
not yet been reported in literature. Regarding Oceania,
a publication from 2016 estimated the occurrence of C.
difficile infection in Australia to account for approximately
12,700 cases between 2011 and 2012 [27] with a hospital-
isation cost of approximately AU$ 19,000 per patient based
on Bond et al. (2017) [28].
Initial treatment consists of metronidazole, vancomycin,
or fidaxomicin administration. Unfortunately, a consider-
able number of patients will suffer relapse up to 3 months
post-treatment [29–31]. Faecal microbiota transplantation,
as a last therapeutic option, consists of the administration
of stool from a healthy donor to the patient, hence trans-
ferring the donor’s microbiome [32, 33]. The interest of
the scientific-medical community for faecal microbiota
transplantation, also called faecal bacteriotherapy, or fae-
cal enemas, increased over recent years, as projected in
the number of scientific publications (see Fig. 1).
Evidence for faecal microbiota transplantation
In 2013, the first randomized controlled open-label clin-
ical trial examining the therapeutic advantages of faecal
microbiota transplantation versus vancomycin treatment
was published by van Nood et al. [34]; they randomly
assigned 43 patients (41 patients completed the study)
with recurrent C. difficile infection to one of the 3 treat-
ment regimens: (I) patients received a short vancomycin
treatment (4–5 days of 500 mg 4 times/day), followed by
a bowel lavage and faeces transplant via a nasoduodenal
tube (17 patients with 1 patient excluded during the
study), (II) vancomycin treatment (500 mg 4 times/day
during 14 days) (13 patients with 1 patient excluded dur-
ing the study), and (III) vancomycin treatment (500 mg
4 times/day during 14 days) with bowel lavage at day 4–5
of the treatment (13 patients). Given the distinct effective-
ness of faecal microbiota transplantation, compared to the
vancomycin treatment, the clinical trial was terminated
early, and the planned 40 patients per treatment regimen
were not obtained. Patients were considered cured when
they remained free of relapse during the 10 weeks follow-
ing the start of the treatment. In total, 13 patients who re-
ceived faeces transplantation remained relapse-free during
10 weeks following the start of the treatment, 3 patients
experienced relapse and received a second transplant,
yielding a total of 15 out of 16 patients that were disease-
free at the end of the study. The study group that received
vancomycin treatment, without bowel lavage, showed 31%
of the patients to remain relapse-free and 23% of the pa-
tients remained disease-free in the group that received
vancomycin treatment and bowel lavage [34]. Despite
these promising results, Vyas et al., warn to be cautious
considering the evidence for faecal microbiota transplant-
ation. These authors argue that although ‘there is ample
evidence of the effectiveness of faecal microbiota trans-
plantation from case series and case reports, the lack of
sufficient randomized controlled trial data still hinders it
from becoming a federally approved or broadly accepted
procedure’. These authors also draw the attention to the
study limitations, for example the absence of blinding
regarding data collection and the low number of in-
cluded patients [8]. Additionally, Vyas et al. experience
the current screening procedures as potentially detri-
mental since the screening process takes days to weeks,
hence potentially missing intermittently infected (e.g.
HIV) donors [8]. For example HIV is known to have a
window period, which is the time between the infection
and the moment a certain laboratory test will be able to
detect the HIV infection. Depending on the applied
HIV test, a newly infected faeces donor might be missed or
the faeces donor might get infected in the period between
HIV testing and faeces donation, hence yielding a serious
risk to the patient transplanted with the faeces [35].
After the first randomized controlled trial, as performed
by van Nood et al. [34], additional randomized controlled
studies have been published [36–40]. A brief discussion of
the randomized controlled trials regarding C. difficile infec-
tion treatment via faecal microbiota transplantation, that
followed van Nood et al. [34], is provided. Kelly et al.
(2016) compared the effect of autologous faeces transplant-
ation (placebo) versus allogeneic faeces transplantation in-
cluding a total of 46 patients, who experienced at least 3
bouts of C. difficile infection, in the randomized controlled
double-blind two-center study. Faeces was transplanted via
colonoscopy and Kelly et al. observed that allogeneic faeces
transplantation prevented diarrhea up to 8 weeks post-
transplantation in 20 out of 22 patients; 15 patients out of
24 were considered cured in the autologous faeces
Fig. 1 Number of publications per year concerning faecal microbiota
transplantation found by a PubMed search (search: faecal microbiota
transplantation OR fecal microbiota transplantation)
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transplant-treatment arm. However, the cure-rate of the
patients who received donor stool was liable to the study
site where the transplantation occurred; this might be,
according to the authors, explained by clinical differ-
ences between the 2 study sites [37].
Jiang et al. (2017) examined the effect of fresh, frozen
or lyophilized faeces (from healthy donors) when admin-
istered via colonoscopy to subjects with at least 3 bouts
of C. difficile infection in a randomized double-blind
study. Jiang et al. concluded that 87% of the patients was
C. difficile infection-free up to 2 months after the faeces
transplantation: 25/25 patients were disease-free when
fresh faeces was transplanted, 16/23 were not suffering a
C. difficile relapse when they received lyophilized faeces
and 20/24 patients were considered cured when they re-
ceived frozen faeces [36]. These observations might
seem to be in conflict with the observations of Lee et al.
(2016); Lee et al. performed a multi-center study (6 sites)
enrolling 232 patients with recurrent C. difficile infection
in a randomized double-blind non-inferiority trial with
114 patients receiving fresh faeces via enema and 118
patients receiving frozen faeces by enema. In the modi-
fied intention-to-treat population, 111 patients received
fresh faeces and 108 received frozen faeces and in the
per-protocol population, 87 received fresh faeces and 91
frozen faeces respectively. Both the per-protocol popula-
tion and modified intention-to-treat population demon-
strated non-inferiority between fresh and frozen faeces
at a non-inferiority margin of 15% regarding diarrhea
and adverse events 13 weeks post-treatment [38].
A randomized controlled open-label pilot study was
published in 2014 by Youngster et al. where they investi-
gated the impact of the route of administration (via colon-
oscopy or via a nasogastric tube) in 20 patients with
recurrent C. difficile infection, equally divided over the 2
treatments. Youngster et al. concluded that the route of
administration appears to yield comparable diarrhea reso-
lution without relapses up to 8 weeks post-transplantation
and improved self-reported health scores with an overall
cure rate of 90% [39].
Cammarota et al. (2015) performed an open-label ran-
domized controlled trial to compare the effect of faeces
transplantation via colonoscopy (consisting of vanco-
mycin treatment 125 mg 4 times/day, bowel lavage at
day 1–2 and subsequent faeces transplantation) versus
vancomycin treatment (10 days of 125 mg 4 times/day
and a subsequent pulse-treatment with 125–500 mg/day
during at least 3 weeks every 2–3 days) in a patient
population (39 patients were randomized over the treat-
ments) with recurring C. difficile infection, hence more
or less resembling the study of van Nood et al. [34]. Pa-
tients were considered cured by Cammarota et al. when
they remained relapse-free 10 weeks after the treatment.
Comparable with van Nood et al. [34], the study by
Cammarota et al. was terminated after an interim ana-
lysis with finally 90% (18/20 patients) of the patients that
received (one or more) faeces transplants considered
cured and 26% (5/19 patients) of the vancomycin treat-
ment group considered cured [40].
The single-center, open-label, randomized trial performed
by Hota et al. (2017) investigated the effectiveness of vanco-
mycin treatment versus faecal microbiota transplantation
for recurrent C. difficile infection (at least 2 laboratory
confirmed episodes of C. difficile infection and prior
vancomycin treatment during these bouts). The number
of participants was limited following an interim analysis,
yielding 16 patients allocated to the faecal microbiota
treatment arm (faeces transplantation via an enema pre-
ceded by a 14 days vancomycin treatment consisting of
125 mg every 6 h) and 12 patients received a gradually de-
creasing, vancomycin treatment during 6 weeks (125 mg
vancomycin every 6 h the first 2 weeks and gradual treat-
ment tapering the consecutive 4 weeks). Patients were
considered cured if no C. difficile relapse occurred
120 days following the intervention. Finally, 56% (9/16) of
the patients that received faecal microbiota transplant-
ation and 42% (5/12) of the patients under vancomycin
treatment experienced a C. difficile relapse, making the
authors to conclude that a single-faecal microbiota trans-
plantation is not significantly different from vancomycin
treatment when patients with recurrent C. difficile infec-
tion are confronted with a new C. difficile episode [41].
Not only randomized controlled trials, but also various
systematic reviews and meta-analyses covering faecal
microbiota transplantation for (recurrent) C. difficile in-
fection have also been published [42–50] with the most
recent one published in 2016 [42].
Gough et al. (2011) evaluated the effect of faecal
microbiota transplantation on recurrent C. difficile infec-
tion. To do so, they included in their systematic review
317 patients, originating from 8 countries over a period
of 53 years, from a total of 27 case series and case reports.
They concluded that (I) 92% of all included patients expe-
rienced disease resolution, (II) faecal microbiota trans-
plantation is therefore a suitable treatment for recurrent
C. difficile infection, (III) treatment effectiveness is highly
depend on for example the route of administration and
the pre-treatment the patient receives prior to faeces
transplantation, and (IV) identified several limitations,
for example: the lack of uniformity across the studies
(for example definitions), the lack of standardisation
(for example pre-transplantation treatment), heterogen-
eity across patients, potential publication bias and the
need of randomized controlled trials [47].
Comparable, Sofi et al. only included retrospective
studies and case reports in their systematic review from
2012 to investigate the effect of faecal microbiota trans-
plantation for C. difficile infection. However, no major
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overlap is apparent between the included publications by
Sofi et al. [49] and Gough et al. [47]. From a total of 25
publications, 289 patients were included by Sofi et al. for
data analysis, demonstrating a total disease resolution of
approximately 91%. The authors mention as limitations
of their meta-analysis: possible publication bias, lacking
uniformity in the faecal microbiota transplantation pro-
cedure (for example different quantities of infused faeces)
and missing variables (for example time between diseases
onset and treatment). Nevertheless, they conclude that
faecal microbiota transplantation is an effective and safe
treatment for C. difficile infection [49].
In the systematic review performed by Guo et al. (2012),
the authors also aimed to investigate the evidence for fae-
cal microbiota transplantation as treatment for C. difficile
infection. As the included publications majorly converge
with the publications applied by Sofi et al. [49] and Gough
et al. [47], this meta-analysis is also solely based on case
series and case reports. In total, 7 publications are retained
by the authors, yielding a total of 124 patients. As previous
meta-analyses concluded, Guo et al. also conclude that
faecal microbiota appears to be a promising treatment
for C. difficile infection since approximately 80% of the
included patients experienced disease resolution. The
limitations they identify are in line with previous authors,
encompassing among others, the need for randomized
controlled trials [50].
The systematic review and meta-analysis of Kassam et
al. in 2013 also aimed to investigate the evidence for fae-
cal microbiota transplantation as treatment for C. difficile
infected individuals. The meta-analysis was conducted on
the data from 273 patients, extracted from 11 retained
publications, which are all included in the study of Sofi et
al. [49] and show a large convergence with Gough et al.
[47] and Guo et al. [50]. Kassam et al. provide in their
publication the argumentation why the meta-analyses of
Gough et al. [47] and Guo et al. [50] have, to their opinion,
limitations. The authors also demonstrate a cure rate
above 90% and do also conclude that faecal microbiota
transplantation is a promising treatment for C. difficile
infection and do also address the need for randomized
controlled trials [48].
O’Horo et al. (2014) extended the scope of their sys-
tematic review and meta-analysis towards 8 different
treatments (metronidazole, vancomycin, fidaxomicin,
nitazoxanide, rifampin, immunoglobulins, probiotics and
faecal microbiota transplantation) for C. difficile infec-
tion. Considering faecal microbiota transplantation, a
total of 33 publications with the majority of these publi-
cations being included in the previously discussed sys-
tematic reviews, are discussed. The data of 609 patients
were analysed in this meta-analysis; data obtained pre-
dominately from case reports or case series and only 2
prospective trials and 1 randomized controlled trial [34].
In conclusion, O’Horo et al. find faecal microbiota trans-
plantation a feasible option for C. difficile treatment, but
they pinpoint the need of more randomized controlled tri-
als [45].
Several other authors also performed meta-analyses
following previous meta-analyses and continued to in-
clude new studies in their systematic reviews. For example
Cammarota et al. also performed a systematic review in
2014, including 20 case series, 15 case reports and 1 ran-
domized controlled trial, i.e. published by van Nood et al.
[34], which have majorly already been included in previ-
ous systematic reviews. The authors performed their
meta-analysis on 536 patients in total and concluded that
87% of them benefited from faecal microbiota transplant-
ation for C. difficile treatment [44]. Dodin et al. identified
at their turn in 2014, 20 clinical reviews, 6 case reports, 2
clinical trials, 1 randomized controlled trial and 1 meta-
analysis in their systematic review. They also conclude
that faecal microbiota transplantation has a place in the
treatment of C. difficile infection, but several unmet needs
needed to be addressed to obtain additional evidence, es-
pecially the need of additional clinical trials/randomized
controlled trials [46].
Bagdasarian et al. investigated both the preferred
method of diagnosis and treatment of C. difficile infec-
tion in their 2015 systematic review. However, no meta-
analysis was performed and they base their conclusions
on the publications they retrieved. Regarding C. difficile
treatment, they conclude that depending on the severity
of the infection, metronidazole, vancomycin or fidaxomi-
cin are preferred. According to the authors, faecal
microbiota transplantation is supported by increasing
evidence [43].
The most recent meta-analysis dates back to 2016 and
was performed by Li et al. The authors focussed in their
publication on the long-term effects and safety of faecal
microbiota transplantation for C. difficile treatment. They
included 611 patients from in total 18 publications, several
already included in aforementioned meta-analyses. Among
the included studies, no randomized controlled trial was
included and the included studies are retrospective, pro-
spective case series or retrospective cohort studies. Finally,
they argue that faecal microbiota transplantation has a pri-
mary cure rate of approximately 91% with an overall recur-
rence rate of approximately 6%. Serious adverse events
were not identified by Li et al., with the most frequent ad-
verse events being classified as transiently and self-limiting.
As other authors, they also advocate the need for random-
ized controlled trials to increase the evidence [42].
In summary, these systematic reviews and meta-analyses
conclude that, despite some publication-specific shortcom-
ings, faecal microbiota transplantation for (recurrent) C.
difficile infection is a promising treatment. However, some
systematic reviews and meta-analyses also point towards
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the need of more high-quality studies, for example cohort
studies and randomized controlled trials to confirm long-
term effects (both efficacy and safety).
Other conditions, for example inflammatory bowel dis-
ease and more specific ulcerative colitis, have also been
subjected to systematic reviews and meta-analyses
[51–55]. In general, the various authors conclude that
faecal microbiota transplantation might be an effective
treatment of ulcerative colitis, but additional well-
designed studies, for example randomized controlled
trials, are essential to obtain more evidence.
The increasing evidence has urged several expert groups
to issue guidelines on the indications for faecal microbiota
transplantation and standardized methods to perform the
transplantation [56–60].
Faecal microbiota transplantation: Viewpoint
regulatory authorities
In 2017, a globalized, common position regarding faecal
microbiota transplantation regulations is still lacking.
The entire spectrum of regulatory statuses is currently
present, ranging from non-existing to strictly regulated.
In 2012, the Competent Authorities on Substances of
Human Origin Expert Group of the European Union
concluded that faeces transplantation is not covered by
the European Human Tissue Directive 2004/23/EC [61, 62].
The discussion was reopened in June 2014 and the
regulatory uncertainty in the European Union was read-
dressed by the Competent Authorities on Substances of
Human Origin Expert Group during discussions held con-
cerning the regulatory status of human milk and faeces
donation [63]. Consecutively, the European Commission
vowed in consulting their legal service asking (I) ‘Should
human milk and/or faeces be considered as falling within
the scope of the Human Tissue Directive 2004/23/EC’ and
(II) ‘If not, could such substances be regulated under the
mandate laid down in Article 168(4) of the Treaty on the
Functioning of the European Union?’ [61]. To comply with
Directive 2004/23/EC, the substance must be a ‘Tissue’ or
‘Cell’ and be intended for ‘Human application’. According
to the European Commission, both criteria can be con-
sidered as being met since both human milk and faeces
contain ‘Cells’. Because faeces and human milk are not
administered because of the presence of human ‘Cells’;
they are administered for the other components (for ex-
ample nutrients in the case of human milk or bacteria/
bacterial components in the case of faeces), the Euro-
pean Commission concluded that faeces transplantation
is not covered by Directive 2004/23/EC [61]. Consecu-
tively, the European Commission argues that individual
Member States are free to regulate faecal microbiota
transplantation on a national level [61, 64], however
only few EU member states have imposed faecal micro-
biota transplantation regulatory demands until now and
most European countries have no regulation on faecal
microbiota transplantation at all. For example, the Su-
perior Health Council of Belgium argued in 2015 that
currently unknown active substance(s) urges them to
consider faecal microbiota as a human body tissue [65].
However, the Superior Health Council of Belgium also
acknowledged in March 2015 that, in the future, faecal
microbiota can evolve towards the status of medicine
when the product becomes a more specified product
concerning the composition of the active substance(s) or
the possibility of an industrial production process [65].
Another position is reflected by the National Security
Drug Agency of France (Agence National pour la Sécur-
ité du Médicament), which issued in March 2014 that
faecal microbiota is to be considered as a pharmaceutical
drug [66, 67].
Austria has the most liberal point of view: the Federal
Office for Safety in Health Care argues that faecal micro-
biota transplantation is to be considered as a therapeutic
intervention, explicitly not applying to the definition of a
drug as specified in the Austrian Medicines Act, neither
being subject to the Medical Devices Act or to the
Austrian Transplantation Act [68]. To provide medical
practitioners some guidance, the Austrian Society of
Gastroenterology and Hepatology, in cooperation with
the Austrian Society of Infectious Disease and Tropical
Medicine and the Austrian Agency for Health and
Food Safety, issued in 2014 a faecal microbiota trans-
plantation consensus guideline. Given the lack of suffi-
cient evidence for other conditions than C. difficile
infection, the consensus guideline recommends the use
of faecal microbiota transplantation for other indica-
tions under the setting of clinical trials [68, 69]. Hence,
faecal microbiota transplantation is currently available
in Austria for patients suffering from C. difficile infec-
tion, while other indications can be treated under the
settings of a clinical trial.
The United States of America Food and Drug Adminis-
tration stated in May 2013 that faecal microbiota trans-
plantation is considered to meet the description of a drug,
hence requiring an Investigational New Drug application
prior to conducting a faecal microbiota transplantation.
Various stakeholders addressed their concerns, indicating
this time-consuming action might restrain patient’s access
to this treatment. The Food and Drug Administration
(USA) acknowledged this concern 6 weeks later and until
today, the necessity to file an Investigational New Drug ap-
plication was revoked for recurrent C. difficile infections.
Although faecal microbiota transplantation retains the drug
status, currently this policy of tolerance remains [70]. In
summary, patients suffering from C. difficile can be treated
by faecal microbiota transplantation in the USA, but the
situation can be considered precarious as the Food and
Drug Administration can revoke their policy of tolerance.
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Finding the right balance
Given the interaction of the gut microbiota with various
physiological processes, both in health and disease, some
argue that the gut microbiota should be envisaged as a
separate, individual organ. Hence, faecal microbiota
transplantation can be considered in that point of view
as an organ transplantation with corresponding screen-
ing standards [8, 71, 72].
Smith et al. strikingly compared in 2014 current faecal
microbiota transplantation risks with the HIV and hepa-
titis infections originating from blood-donation during
the 1970 and 1980’s, a period HIV was largely unknown
[70]. Considering the possible effect of the microbiome
in a variety of diseases, this concern might in future
years be proven significant [48]. Hence, a careful and po-
tentially ‘over-regulating’ approach is justified as a safety
precaution regarding unknown possible long-term ad-
verse effects. However, given the acute character and the
undeniable mortality rates, the apparent therapeutic su-
periority of faecal microbiota transplantation compared
to standard antibiotic therapy and the persistent suffer-
ing of the patient affected by C. difficile, hindering pa-
tients access to the faecal microbiota transplantation
treatment can be considered as inhumane.
Alternative legislation has been proposed by Sachs et
al. in 2015. They propose to construct a hybrid regula-
tory approach, comparable as performed for blood and
cord blood [73]. Smith et al. consider the current faecal
microbiota transplantation regulation as both over- and
under-regulating as C. difficile infections can be treated
by faecal microbiota transplantation without stringent
limitations. In the USA, the Investigational New Drug
applications necessary for other disorders imposes a dis-
tinct barrier for clinical researchers to examine the use-
fulness of faecal microbiota transplantation for other
pathologies [70]. Regulators should keep in mind that,
contrary to other treatments, faecal microbiota trans-
plantation can be performed by the patient itself without
much obstacles. The procedure can easily be conducted
using standard kitchen devices and already do-it-yourself
faecal microbiota transplantation videos are freely avail-
able [74]. The author of one of the videos also explicitly
mentions that he was suffering for over 12 years from
ulcerative colitis and provides viewers with a do-it-
yourself faecal microbiota transplantation manual; this
video was aired in 2013 and attracted around 80,000
views 4 years later [61]. In brief, the video describes and
demonstrates how faeces from a donor is obtained,
blended in a kitchen blender (the author luckily men-
tioned to use a dedicated blender) with deionised water
with salt added to obtain home-made saline, how the
resulting suspension is to be sucked into a rectal syringe
and how the faeces suspension must be retained in the
gut to allow it to reach as much of the colon as possible.
However, do-it-yourself faecal microbiota transplantation
imposes various risks, for example: health-risks, legal li-
ability and possible long-term effects. In the Youtube®
video, the author mentions that relatives are the most
appropriate donors since ‘you can trust that you know
their medical history, hopefully you can at least’, never-
theless the author of the Youtube® video advices to per-
form several laboratory tests to assess the donor’s health
status [74]. Although, it can be expected that some pa-
tients do not wish to test their faeces donor because
‘they trust their donor is healthy’, hence exposing them-
selves to possible infections the donor might not be
aware of because he/she was infected lately with for ex-
ample HIV or Hepatitis, among others. Additionally,
donor assessment should be strictly reserved to a person
with a medical training.
The video also advices on the use of certain pharma-
ceutical drugs, near the end of the video, to accommodate
with some inconveniences faecal microbiota transplant-
ation might cause when administered via a rectal syringe,
for example prednisone in advance of the faecal
microbiota transplantation. Altering/starting medication
schemes can impose various health risks and must be con-
ducted by medically trained professionals.
The lack of anonymity of faeces donation, and the
largely unknown long-term effects various faecal micro-
biota transplant experts put forward, can have (legal) li-
ability issues in the future which do-it-yourself patients
are most probably not aware of.
Even more striking is a video from 2013 where a patient
testifies how she received as a 10 year old girl, do-
it-yourself faecal microbiota transplantation by her
mother [75].
Hence, denying patients access due to a too stringent
regulation can redirect desperate patients towards these
uncontrolled and potentially harmful do-it-yourself pro-
cedures, or to quote the author of the do-it-yourself fae-
cal transplant book ‘Poop Power – story and guide
book’: ‘While I would have preferred to work with a doc-
tor, and almost did, the process is cumbersome and many
doctors do not want to do this procedure because of ob-
stacles put in place by hospitals and government regula-
tions. In the meantime this procedure can be done at
home with proper guidance’ [76].
Another consideration that should be reflected in the
regulation of faecal microbiota transplantation are the
possible advancements probably made in near future [8].
Administering selected microbiota as a capsule differen-
tiates it from a medical intervention, meeting more the
definition of a pharmaceutical drug. Evolving away from
the current faecal material, obtained from donors, to-
wards synthetic/purified faecal microbiota transplant-
ation material can lower the donor-associated risks, e.g.
pathogens, and pave the way for industrial production
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[77]. This potential future for faecal microbiota trans-
plantation strengthens the urgent need of an applicable
and suitable regulatory status.
A pragmatic regulatory approach for a quickly
evolving therapy
The current situation, as well the potential evolutions in
the nascent field of faecal microbiota transplantation, pos-
sibly allowing a shift from faecal transplantation towards
more defined products containing microorganisms, ur-
gently calls for a regulatory frame which grants patients
access to faecal microbiota transplantation as a matter of
principle. An urgent need for a regulatory framework is
persistent for reasons of clarity, given the vast amount of
poor quality studies and case reports apparent until now
in literature and the lack of a standardized procedure.
Baxter et al. strikingly draw the attention towards the
absence of a structured follow-up of faecal microbiota
transplantation patients [78].
Structured donor selection, quality control and follow-
up of faecal microbiota transplantation could be based
on blood and blood products (e.g. cord blood) regula-
tions as previously argued by Sachs et al. [73]. Despite
various resemblances between blood (products) and fae-
ces, for example the need of donors and the risk of in-
fecting the recipient, we identify several properties of
faeces that urge another regulatory approach.
The exact mechanism of action of faecal microbiota
transplantation is still to be resolved. In other words, the
exact contributing micro-organisms and/or their metab-
olites are still to be discovered. The functional compo-
nents of blood (products) on the other hand, are more
straight-forward and well-known, for example: thrombo-
cytes are isolated and administered to a patient with
thrombocytopenia.
Until now blood cannot be produced in vitro and donor
involvement is mandatory. Faecal microbiota transplant-
ation has the opportunity to evolve towards a defined
bacteria-based product, a ‘bacteriaceutical’, hence faecal
microbiota transplantation can be considered as the initial
step. In a certain way, faecal microbiota transplantation
can be compared to opium. Before the isolation and chem-
ical synthesis of opioids, patients received the opioids as a
crude/mixture/extract from Papaver somniferum. Compar-
ably, the necessary gut bacteria/bacterial components for
patients suffering intestinal dysbiosis are currently adminis-
tered as being part of faeces, but these necessary micro-
biota and/or their products might in the near future be
identified and administered without faeces being involved.
The general disease-healing potential of faecal micro-
biota transplantation is just being explored with cur-
rently ulcerative colitis as the most promising example.
Hence, the regulatory framework must accommo-
date evolutions of the product and must encourage
conducting clinical trials to investigate the possible
advantages of faecal microbiota transplantation for
other conditions.
Therefore, an interesting possibility to regulate faecal
microbiota transplantation, given its distinct complexity,
could be based on current regulations. Extending the
scope of the gene-, cell-, and tissue therapeutics allows
inclusion of faecal microbiota transplantation in this glo-
bal product group, e.g. the Advanced Therapy Medicinal
Products in the European Union, this regulatory approach
will allow to meet the necessities that are defined in
Table 1 and will facilitate possible, future advancements.
As a matter of clarity, the argumentation why faecal
microbiota transplantation must be regulated based on
the cell-, tissue-, and gene-regulation has been limited to
the situation in the European Union. However, a compar-
able argumentation can also be constructed based on the
legal situation of cell-, tissue-, and gene-therapeutics in
other countries, e.g. USA, Japan, Canada or Australia.
The European Advanced Therapy Medicinal Products
Regulation came into act in 2007 and was issued to re-
spond to the fast scientific evolutions in the field of tis-
sue engineering, gene therapy and somatic cell therapy,
giving the centralized European Medicines Agency the
authority to regulate these products in the entire Euro-
pean Union. Compared to other pharmaceutical drugs,
these cell-, tissue- and gene-based products have more
specific needs regarding assessment of efficacy, safety
and quality.
Currently, the European Advanced Therapy Medicinal
Products regulation can regulate various products: gene
therapy medicinal products are considered products
aiming to alter/repair/replace gene(s) or the effect is
linked to the administered nucleic acid(s) or the product
resulting from the genetic expression [79], whereas tissue-
and cell-based therapy medicinal products in essence con-
tain human or animal cells or tissues, viable or non-viable,
engineered or not, with or without additional products
(e.g. bio-molecules), with the aim to exert a pharmaco-
logical, immunological or metabolic effect [78]. On a legal
basis, the gene-, cell-, and tissue-regulation appears to be
able to encompass the complexity of faecal microbiota
transplantation, since faeces is obtained from a human
donor and is transferred to a human receptor, hence
encompassing an infection risk. The human microbiome,
more specific the gut microbiome, is considered as a ne-
cessary part of our body since dysbiosis of the gut micro-
biome is linked to a variety of diseases, as for example C.
difficile infection. Currently, this microbiome-component
is administered as the complex mixture faeces is. A histor-
ical parallel can be identified with the evolution of recom-
binant proteins, with insulin serving as an example.
Insulin was discovered in the early twentieth century as
the component that regulates the blood glycaemia, with a
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Nobel prize awarded in 1923 for its discovery, but it would
take until the 1980’s [80] before the first synthetic, human
insulin was available to patients. In the intermittent de-
cades, diabetics were administered insulin from bovine
and/or porcine origin [81]. Comparably, the necessary
components of the faecal transplant, although from mi-
crobial origin and thus currently not directly falling
under the gene-, cell-, and tissue regulation, might soon
be identified and administered as such, without the
need of transplanting complete faeces. The gene-, cell-,
and tissue regulations were established to cope with the
potential fast evolutions of these therapeutics. Analogue,
this regulation is able to cover the possible advances made
in faecal microbiota transplantation, since this regulation
has been written with an open view to remove as much as
possible legal obstacles for the fast bench-to-bed transition
of promising treatments.
Additionally, a majority of the risk/benefit balance
concerning faecal microbiota transplantation, e.g. trace-
ability, quality, including Good Manufacturing Practice,
pharmacovigilance and information to the patients, are
already covered by the gene-, cell- and tissue regulation
of the European Union [82]. For example, the regulation
defines the conditions that must be met when human
cells and tissues are donated: both the donor and recipi-
ent must be anonymous, altruism of the donor must be
the driving force to donate, hence donation must be vol-
untary and unpaid. At the same time, a key concern of
current faecal microbiota transplantation, i.e. the long-
term effects, is faced by the legal demand to establish
appropriate measures to monitor any possible adverse
reaction over time. Hence, a suitable risk management
system capable of addressing risk identification, character-
isation, prevention and minimisation plus being capable of
assessing the therapy effectiveness must be in place. Cur-
rently, if faecal microbiota transplantation is performed, it
remains unclear how traceable the faeces transplantation
has been performed since no clear legal demands are de-
fined. The Advanced Therapy Medicinal Product regula-
tion defines strict traceability demands that need to be
met: patient, donor, the product/starting material must be
recorded in a traceable manner for at least 30 years after
the treatment has been performed. The facility where the
product has been administered must be able, via traceabil-
ity, to link the patient to the specific product adminis-
tered. According to the current regulation, if the holder of
the marketing authorisation would be unable to fulfil this
legal demand (e.g. bankruptcy), the data must be trans-
ferred to the European Medicines Agency.
Besides, this legal framework provides in a formal, tai-
lored clinical trial status, possibly leading to a formal mar-
keting authorization, but also in the possibility to flexibly
exercise the hospital exemption [82], under strictly defined
conditions. The hospital exemption in the European
Union is applicable when an Advanced Therapy Medicinal
Product is prepared on a non-routine basis, but with spe-
cific quality standards, in a hospital setting for administra-
tion in the same European Union state. The aim of this
hospital exemption is to meet a medical need of a specific
patient and is administered to this patient under the re-
sponsibility of the medical practitioner [82].
Other stake-holders, for example medical practitioners,
would also benefit by regulating faecal microbiota trans-
plantation according to such a legal framework. The most
Table 1 Principles to be considered for faecal microbiota transplantation regulation
Principle Explanation
Regulatory harmonization The regulation of faecal microbiota transplantation must be comparable around the world. Some countries have
regulated faecal microbiota transplantation ad interim (e.g. by regulatory discretion in the USA), some countries
have a liberal faecal microbiota transplantation regulation (e.g. Austria) and various countries do not have any
legal framework at all regarding faecal microbiota transplantation (e.g. various European Union member states).
Hence, safe and regulated access to faecal microbiota transplantation currently still majorly depends on the
country where the patients are living in.
Patient Empowerment Patients should be empowered and allowed to make informed decisions. Providing patients with adequate,
scientifically sound information to allow them to, together with their physician, weigh the possible benefits and
risks attached to faecal microbiota transplantation and to take an informed decision. From the point of view that
every person must be allowed self-determination regarding their health.
Quality Faecal microbiota transplantation must be conducted with faeces that meets rigorous quality standards (e.g.
absence of pathogens and infectious transmittable diseases) to limit the risks to the recipient.
Donor anonymity Frequently, relatives/partners are donors given their comparable microbiome. Since long-term adverse events
seem until today unclear, one could question donors to be blamed when such long-term adverse events would
occur. Hence faeces donation must be conducted in an anonymous, but traceable, way.
Efficacy The efficacy of faecal microbiota transplantation must be monitored by an independent organisation (e.g. the
competent authorities) to safe-guard patients and to allow the practise of evidence-based medicine.
Information All stake holders must be provided with adequate information. For example, the patient must obtain all relevant
information available and must be made aware of possible long-term risks, possibly currently unknown.
Pharmacovigilance Adequate monitoring of patients though time must be maintained to detect e.g. late adverse effects and to
allow pharmaco-epidemiology and pharmaco-economics.
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straight-forward advantage would be liability when faecal
microbiota transplantation is regulated by law. Currently,
several countries do not have such laws, hence potentially
exposing medical practitioners to law suits due to the
lacking legal framework. In first instance, expanding the
scope of such a legal framework towards faecal microbiota
will, because of the hospital exemption, not cause an im-
mediate cessation of faecal microbiota transplants [67].
Moreover, such a legal framework would encourage the
initiation of clinical studies, e.g. to provide evidence on
the treatment of ulcerative colitis via faecal microbiota
transplantation. On a European level, marketing author-
isation of faecal microbiota for a given disease would im-
mediately grant all citizens of the European Union access
to the treatment [83], avoiding unnecessary replication of
clinical trials due to different regulatory demands per
country. Therefore, we strongly advocate competent
authorities around the world to cooperate on the regu-
latory framework of faecal microbiota transplantation,
since already various countries have adopted, or are work-
ing on, cell-, tissue-, and gene-therapeutic regulations, for
example India [84], Australia [85], Canada [86], USA [87]
and Japan [88].
Conclusion
Including faecal microbiota into the gene-, cell-, and tissue
class will meet the demands of patients, health care practi-
tioners, competent authorities and industry. Faecal micro-
biota transplantation challenges the current regulatory
frameworks due to its complex nature. Therefore we
propose to expand the scope of the various cell-, gene-,
and tissue regulations towards faecal microbiota. Applying
such a regulatory approach globally, will give patients ac-
cess to this potentially life-changing and -saving therapy.
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